Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.82 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.80 |
| ▸ | PDE5A | O76074 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | USP2 | O75604 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412953 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL31061048 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL14262837 | 0.90 | KDM4E (0.94) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL413202 | 0.89 | TGFBR1 (0.86) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL4867505 | 0.89 | ABCG2 (1.00) | TGFBR1MAPK14ABCG2PDE5APOLB | |
| SCHEMBL7434986 | 0.87 | ALDH1A1 (1.00) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL8093527 | 0.85 | ABCG2 (0.82) | ABCG2PDE5AKDM4EALDH1A1POLB | |
| SCHEMBL12316824 | 0.85 | GAA (1.00) | ABCG2PDE5APOLBMAPTTP53 | |
| SCHEMBL3460305 | 0.85 | ALDH1A1 (0.94) | TGFBR1MAPK14ABCG2PDE5AKDM4E | |
| SCHEMBL22201578 | 0.83 | HPGD (0.86) | TGFBR1MAPK14ABCG2PDE5AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| CN-101102787-A | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA INC (US) | 2008-01-09 | — | — | CN | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 24/4885ABCG2 886/4885 |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | TGFBR1 386/4885MAPK14 2828/4885ABCG2 713/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | TGFBR1 795/4885MAPK14 2215/4885ABCG2 439/4885 |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | TGFBR1 4/4885MAPK14 40/4885ABCG2 1096/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 24/4885ABCG2 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.